Posts Tagged ‘tirzepatide’

Cardiovascular Deaths and Insurance Denials of Obesity Care

August 9, 2023 — Yesterday brought us one of the most curious mashups of news  we’ve seen in a while. On one hand we have stories about employers and insurance companies conspiring to deny obesity care to their employees and customers; on the other we have the news that the drug they don’t want to cover actually prevents deaths […]

NICE Says Nope to Tirzepatide

June 29, 2023 — After four exhilarating days of new possibilities for overcoming diabetes and obesity at ADA2023, we had to come back down to earth. The National Institute for Health and Clinical Excellence in the UK stepped up to this task right away. On Tuesday, NICE said nope to recommending tirzepatide use for type 2 diabetes in the […]

ADA2023: A Golden Age of Obesity Medicine?

June 26, 2023 — “We may be on the cusp of an era of astonishing innovation – the limits of which aren’t even clear yet,” writes David Wallace-Wells in the New York Times. Among other breakthroughs, he cites the transformation in care that semaglutide and tirzepatide are bringing for the most prevalent chronic disease in the world – obesity. […]

ADA2023 in San Diego: Watching Tides Roll In

June 24, 2023 — Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]

Coming to Terms with the Biology of Desire

June 5, 2023 — O‌‌ne of the neat tricks of semaglutide and tirzepatide is their unexpected ability to shift the frames of bias through which we look at obesity and human behavior. Neuroscience and behavioral psychology have long told us the human desire for food is not purely a matter of choice. Yet in addressing obesity, weight bias and […]

Greed versus Health and Obesity Care

May 28, 2023 — “Money makes the world go around.” Joel Grey and Liza Minnelli explained this in Cabaret. But sorting it out in healthcare – and specifically in obesity care right now – is quite a challenge. A lot of money is in play and so the tension between greed, health, and obesity care is painfully obvious. The […]

Scratching the Surface with New Obesity Meds

May 9, 2023 — With all the sensational reporting about semaglutide and tirzepatide for obesity – often with the emphasis on weight loss – you might think a revolution is underway. Yes, it is coming. But the truth is that it hasn’t even started yet. At present, for a number of reasons, we are barely scratching the surface of […]

Is Mounjaro Gliding Toward an Obesity Approval?

April 28, 2023 — Tirzepatide, marketed by Lilly under the  Mounjaro brand, may be gliding toward an FDA approval for obesity later this year. A year ago, the first phase 3 study results for tirzepatide in obesity wowed us. Yesterday, Lilly revealed yet another impressive piece of the puzzle – impressive weight reduction in persons who have both obesity […]

OCW2023: The End of Obesity? Not Exactly

March 3, 2023 — An interesting collision of stories is playing out in the media today. It comes at the end of Obesity Care Week and on the eve of World Obesity Day. On one hand, the Economist proclaims that “new drugs could spell an end to the world’s obesity epidemic.” On the other, hand the World Obesity Federation […]

The Most Read Posts on ConscienHealth in 2022

December 16, 2022 — We’re zooming toward the end of 2022, so it’s hard to resist looking back to see which of the posts on ConscienHealth you read the most. We are grateful for the smart and diverse people who take the time to read what we post here. Seeing what captures your attention teaches us a thing or […]